A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection

Trial Profile

A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMMAND-1; HEPCAT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Sep 2012 Planned number of patients changed from 400 to 625.
    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, according to a Bristol-Myers Squibb media release.
    • 30 Sep 2011 Interim results will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in November.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top